Building on the Potential of Our DPX Delivery Technology
IMV’s mission is to push the boundaries of our DPX® technology: a novel delivery platform that is highly versatile and mimics the natural flow of antigens through the immune system, driving a targeted and persistent immune response. Through collaboration and partnership, we aim to expand our DPX-based pipeline to ultimately deliver better and safer treatments to patients.
Our expert scientific team can formulate diverse cargo (such as peptides, whole proteins, RNA, DNA, small molecules, and virus-like particles) into a single formulation to provide simultaneous delivery to the immune system.
Maveropepimut-S (MVP-S) is our lead DPX-based product, currently in multiple Phase 2b clinical trials. MVP-S has demonstrated clinical benefit to patients in a variety of indications, including DLBCL, ovarian cancer and bladder cancer.
We are actively seeking collaboration opportunities to expand our pipeline of DPX-based therapeutics, and for development of our lead DPX-based cancer therapeutic, MVP-S.
Interested in Partnering with Us?
We are interested in discussing potential partnership opportunities in immuno-oncology and other applications of our DPX delivery technology. Please contact us if you have an interest in advancing better and safer therapies.
Contact UsOur partnership with Merck
We have partnered with Merck in two phase 2 clinical trials. The VITALIZE phase 2b study, was initiated in January of 2022, to evaluate the clinical benefit of MVP-S in combination with Keytruda®, Merck’s anti-PD-1 therapy, in patients with r/r DLBCL. An additional goal of this study is to further validate the therapeutic potential of a combination of pembrolizumab, MVP-S and CPA, in PD-L1 positive patients.
The second phase 2 clinical trial was a basket trial, which assessed the effect MVP-S combined with Keytruda® and CPA had on solid tumors, like bladder, liver and MSI-H tumors. The initial data from the metastatic bladder cohort was most prominent and showed that patients benefited from the immunotherapy, especially if they received prior immune checkpoint inhibitor therapy.
Learn More About MerckOur Investigator-Initiated Clinical Programs
With the Providence Cancer InstituteWith the Providence Cancer Institute
In late 2021, we initiated a collaboration with the Providence Cancer Institute in Oregon to conduct an investigator-initiated phase 1B clinical study on MVP-S in HR+/HER2- breast cancer. This study has three arms, and MVP-S will be evaluated in 18 subjects with resectable, non-metastatic HR+/HER2- breast cancer with aromatase inhibitor, and importantly, for the first time in a neoadjuvant setting.
The Providence Cancer Institute is dedicated to surrounding patients with the best, and most compassionate cancer experts who will help coordinate the clinical trials and research. Working together, our organization and PCI have a common mission – to ultimately cure cancer and find better, less toxic ways to do it.
Learn More About PCIPartnering with CHU de Québec Université Laval
The Canadian bioresearch consortium (CQDM) awarded our organization a grant to collaborate with the Centre de recherche du CHU de Québec-Université Laval (CRCHU), and La Fondation du CHU de Québec (FCHUQc).
This collaboration is leading the development of a second immunotherapy leveraging the DPX immune delivery platform, called DPX-SurMAGE. This dual-targeted immunotherapy combines antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously. A Phase 1 clinical trial in bladder cancer, using MVP-S or DPX-SurMAGE, was initiated in early 2022.
Learn More About CHU de Quebec